High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.467
-83.01%
--
--
-0.740
+94.68%
--
--
-0.789
+125.49%
Estimates Revision
The market is revising No Change the revenue expectations for Monopar Therapeutics Inc. (MNPR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 79.76%.
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+79.76%
In Past 3 Month
12 Analyst Rating
Wall Street analysts forecast MNPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNPR is 108.75 USD with a low forecast of 85.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 79.470
Low
85.00
Averages
108.75
High
130.00
Current: 79.470
Low
85.00
Averages
108.75
High
130.00
Raymond James
Christopher Raymond
Strong Buy -> Outperform
downgrade
$142 -> $123
2025-11-14
Reason
Raymond James
Christopher Raymond
Price Target
$142 -> $123
2025-11-14
downgrade
Strong Buy -> Outperform
Reason
Raymond James analyst Christopher Raymond downgraded Monopar Therapeutics to Outperform from Strong Buy with a price target of $123, down from $142. The firm cites a higher risk profile than anticipated for the downgrade. The firm's key opinion leader feedback indicates a "heavier commercial" lift than first imagined for Monopar in Wilson disease. A " higher risk premium to our estimates is warranted here," the analyst tells investors in a research note.
Leerink
Outperform
initiated
$115
2025-11-10
Reason
Leerink
Price Target
$115
2025-11-10
initiated
Outperform
Reason
Leerink initiated coverage of Monopar Therapeutics with an Outperform rating and $115 price target. The firm notes lead asset ALXN1840 produced positive data in the Phase 3 FoCus study, which combined with long-term data and anecdotal reports of substantial patient benefit noted by physicians and the company, provides Leerink with relative optimism that the totality of the data supports a regulatory submission with the FDA and an eventual approval. The firm assumes gross peak sales of about $1.3B for ALXN1840 in Wilson disease. Based on the positive data generated and stage of development, Leerink ascribes a 65% probability of success. Further, the firm thinks shares can move higher over the next 12+ months with regulatory progress and a commercial launch on the horizon.
H.C. Wainwright
H.C. Wainwright
upgrade
$70 -> $105
2025-09-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$70 -> $105
2025-09-29
upgrade
Reason
H.C. Wainwright raised the firm's price target on Monopar Therapeutics to $105 from $70 and keeps a Buy rating on the shares. A recently published peer-reviewed Letter to the Editor in the Journal of Hepatology presented a re-analysis of the Phase II ALXN1840-WD-204 trial, which evaluated copper balance in Wilson disease patients treated with ALXN1840. The letter challenges the sponsor's earlier findings, arguing they were based on a flawed methodology that considered only urinary and fecal excretion, according to a research note to investors. The re-analysis showed that ALXN1840 actually improved copper balance over the course of the study, the firm reports.
Piper Sandler
Biren Amin
Overweight
maintain
$76 -> $95
2025-09-25
Reason
Piper Sandler
Biren Amin
Price Target
$76 -> $95
2025-09-25
maintain
Overweight
Reason
Piper Sandler analyst Biren Amin raised the firm's price target on Monopar Therapeutics to $95 from $76 and keeps an Overweight rating on the shares. The firm notes the company highlighted a new analysis of the Phase 2 ALXN1840-WD-204 study that disputes the earlier conclusion regarding ALXN1840's lack of effect on copper excretion in patients with Wilson Disease. By considering all pathways of copper loss, beyond just fecal and urinary excretion, this analysis demonstrates that ALXN1840 effectively promotes copper excretion. Herein, Piper also compares and contrasts the recent accelerated approval of Stealth Bio's elamipretide in Barth syndrome, as it sees several parallels that bode well for ALXN1840's potential approval with NDA filing expected in Q1 2026.
Chardan
Keay Nakae
Buy
upgrade
$60 -> $85
2025-09-25
Reason
Chardan
Keay Nakae
Price Target
$60 -> $85
2025-09-25
upgrade
Buy
Reason
Chardan analyst Keay Nakae raised the firm's price target on Monopar Therapeutics to $85 from $60 and keeps a Buy rating on the shares. In a letter to the editor published in The Journal of Hepatology, a new analysis of data showed that ALXN1840 rapidly improves copper balance in Wilson disease patients, the analyst tells investors in a research note.
Cantor Fitzgerald
NULL
to
Overweight
upgrade
$74 -> $109
2025-09-24
Reason
Cantor Fitzgerald
Price Target
$74 -> $109
2025-09-24
upgrade
NULL
to
Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Monopar Therapeutics to $109 from $74 and keeps an Overweight rating on the shares.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Monopar Therapeutics Inc (MNPR.O) is -26.68, compared to its 5-year average forward P/E of -6.21. For a more detailed relative valuation and DCF analysis to assess Monopar Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.21
Current PE
-26.68
Overvalued PE
0.75
Undervalued PE
-13.17
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 1958.57% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 1958.57% over the last month.
Sold
Bought
MNPR News & Events
Events Timeline
(ET)
2025-11-13
08:02:27
Monopar Therapeutics Announces Quarterly EPS of 48 Cents, Exceeding Consensus Estimate of 40 Cents
2025-11-09 (ET)
2025-11-09
13:31:07
Monopar unveils fresh data and analyses from the Phase 2 ALXN1840-WD-204 study
2025-09-24 (ET)
2025-09-24
10:25:24
Monopar Soars Following Doctor's Letter Published in Journal of Hepatology
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/f5745fb62248cce8efd59cde436b4f646c0c1ad61a2cc75c51118b88feebe48f.png)
Preview
6.0
11-14BenzingaHome Depot Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
6.0
11-14BenzingaChardan Capital Reaffirms Buy Rating on Monopar Therapeutics with $100 Price Target Intact
Preview
6.0
11-10BenzingaChardan Capital Reaffirms Buy Rating on Monopar Therapeutics and Increases Price Target to $100
Sign Up For More News
People Also Watch
FAQ
What is Monopar Therapeutics Inc (MNPR) stock price today?
What is Monopar Therapeutics Inc (MNPR)'s business?
What is the price predicton of MNPR Stock?
What is Monopar Therapeutics Inc (MNPR)'s revenue for the last quarter?
What is Monopar Therapeutics Inc (MNPR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Monopar Therapeutics Inc (MNPR)'s fundamentals?
How many employees does Monopar Therapeutics Inc (MNPR). have?